CompletedNCT01031927
Sarcosine for obsessive-compulsive disorder
About this title
N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)
Read the official source — NCT01031927Medication studyAges 18–65TaiwanOCD
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- TaichungSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJune 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- China Medical University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Taiwan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01031927
- Official title
Show the full official title
Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Taichung
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is China Medical University Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including N-methyl glycine.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
